VALN · Valneva SE

Valneva SE successfully completed a reserved offering, raising approximately €37 million through the issuance of 15,893,817 new ordinary shares. The financing structure includes warrants attached to each share, offering the potential to raise an additional €47 million if fully exercised, bringing the total potential proceeds to €84 million. The offering was led by existing investor Frazier Life Sciences and included participation from several new and existing healthcare-focused institutional investors. The issue price of €2.33 per ABSA represented a discount to the recent trading price, resulting in immediate dilution of 9.1% for existing shareholders. The structure provides investors with warrants exercisable at a 25% premium to the reference price, aligning investor interests with future stock appreciation. Proceeds are intended to be split evenly between advancing the company's vaccine pipeline, including its Lyme disease candidate, and supporting commercial operations and general working capital. Concurrently, Valneva entered into a registration rights agreement, committing to register the securities for resale in the U.S., which provides liquidity path for the investors. The company also noted a further restructuring plan to reduce operating expenses.